Market Overview

Mizuho Raises Price Target For Salix Pharmaceuticals

Related SLXP
Bill Ackman To Investors: 'Deeply And Profoundly' Sorry For The Valeant Fiasco
BMO Still Believes Valeant Is Undervalued

In a report released Tuesday, Mizuho analyst Mario Corso increased the firm's price target on Salix Pharmaceuticals (NASDAQ: SLXP) by 15 percent from $131 to $151.

Analysts at Mizuho are bullish on Xifaxan IBS top line data, anticipating approval in the first half of 2015. Salix's Xifaxan was measured as statistically significant, in a study measuring response rates compared to placebo.

Two more drugs targets are in stage for an NDA re-submission in the next few weeks and approval is projected for the first half of 2015.

Shares of Salix are trading up 11.4 percent at $137.40 in Tuesday's session.

Latest Ratings for SLXP

Mar 2015JefferiesDowngradesBuyHold
Feb 2015UBSDowngradesBuyNeutral
Feb 2015Cantor FitzgeraldDowngradesBuyHold

View More Analyst Ratings for SLXP
View the Latest Analyst Ratings

Posted-In: Mario Corso mizuhoAnalyst Color Price Target Analyst Ratings


Related Articles (SLXP)

View Comments and Join the Discussion!

Partner Center